Replimune’s oncolytic virus, given with nivolumab, won accelerated approval for melanoma that has progressed on immunotherapy — after two prior rejections.
The nationwide recall covers one lot of Tyenne (tocilizumab-aazg) injection after glass particles were found in the vials, a risk of irritation or vein inflammation.
A study of 402 adults found that physical activity and controlled blood sugar in midlife were associated with better preserved thinking skills decades later.
Analyzing antibody “fingerprints” across thousands of people, a deep-learning model spotted markers that flag who is likely to mount a weak vaccine response in advance.
A large Swedish study tracked hundreds of thousands of people and found that those who actually completed a mailed stool test were far less likely to die of colorectal cancer.
Iberdomide is the first approved CELMoD — a next-generation protein degrader — cleared in a three-drug combination for multiple myeloma as early as first relapse.
Nipocalimab wins FDA approval for warm autoimmune hemolytic anemia — a disease in which the immune system destroys the body’s own red blood cells — giving patients their first dedicated therapy.
K2 Therapeutics, a Flagship-style ‘hub-and-spoke’ biotech that in-licenses drug candidates worldwide, named the former Legend Biotech chief as its new leader.
Dutch researchers found that low-dose digoxin — a drug derived from foxglove and costing pennies a day — reduced heart-failure hospitalizations by about 25% in a large placebo-controlled trial.
Otsuka's centanafadine is the first ADHD medicine to block reuptake of all three key neurotransmitters — a new mechanism for adults and children 6 and up.
Reported delays in delivering Nexviazyme — an enzyme therapy for a rare, progressive disease — follow an FDA warning letter over a Sanofi manufacturing site.
Altimmune's pemvidutide reduced heavy-drinking days more than placebo in a Phase 2 study — early evidence that GLP-1-class drugs may curb more than appetite.